Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.
The antigenic structure of normal skin and spleen cells has been investigated following in vivo treatment with the compound DIC. In experiments involving skin grafting in the normal and sensitized host, cross sensitization with a DIC-antigenic lymphoma and 3H-thymidine incorporation by lymphocytes cultured with DIC-treated spleen cells, new antigens on DIC-treated tissues were not demonstrated.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003606:Dacarbazine / Q000494:pharmacology*; D005260:Female; D007939:Leukemia L1210 / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D012867:Skin / Q000187:drug effects / Q000276:immunology*; D016038:Skin Transplantation; D013154:Spleen / Q000187:drug effects / Q000276:immunology*; D014184:Transplantation, Homologous; D014226:Triazenes / Q000494:pharmacology*
D000970:Antineoplastic Agents; D014226:Triazenes; D003606:Dacarbazine